Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
bluebird bio
bluebird bio
Activities:
Research & Development
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
Minaris to manufacture Bluebird Bio therapy for CALD
Early Cerebral Adrenoleukodystrophy is a life-threatening progressive neurodegenerative disease
Ingredients
Refined commercial production spec gets gene therapy EMA go-ahead
US-based Bluebird Bio is working with German apceth Biopharma for commercial manufacturing of its one-time thalassemia therapy that is approved in the EU, not the US
Regulatory
Apceth bullish on manufacturing deal with bluebird bio
The German CDMO will operate as commercial manufacturer in Europe for Zynteglo, bluebird bio's first gene therapy to gain regulatory approval
Manufacturing
Bluebird bio opens lentiviral vector manufacturing facility
The US company’s first facility will produce clinical and commercial supplies of gene therapy vectors, with room for expansion
Pharmaceutical
Collaboration to develop gamma delta CAR T cell product candidates
bluebird bio and Scottish immunotherapy company TC BioPharm, announced a strategic collaboration and license agreement focused on gamma delta CAR T cells
Research & Development
Lonza and Bluebird Bio announce commercial manufacturing agreement
For Lenti-D and LentiGlobin therapies for severe genetic diseases and T cell-based immunotherapies for cancer
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Homing in on cancer targets
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Subscribe now